Skip to main content
SpringerLink
Log in

Die Behandlung der Sialorrhö mit Botulinum-Toxin

Treatment of sialorrhea with botulinum toxin: an overview

  • Übersichten
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Zu einem vermehrten Speichelfluss (Sialorrhö) kommt es bei einer Vielzahl von neurologischen Erkrankungen wie dem M. Parkinson oder der amyotrophen Lateralsklerose als Folge einer Schluckstörung. Eine vermehrte Speichelproduktion wird durch den Einsatz atypischer Neuroleptika in der Psychiatrie beobachtet. Die bisherigen medikamentösen Behandlungsformen waren aufgrund der systemischen anticholinergen Nebenwirkungen und mangelnder Wirkstärke limitiert. Durch die lokale Injektionsbehandlung mit Botulinum-Toxin hat sich in den letzten Jahren eine effektive und nebenwirkungsarme Alternative entwickelt. Der Artikel gibt eine Übersicht über den derzeitigen Kenntnisstand und die Studienlage zur Behandlung der Sialorrhö mit Botulinum-Toxin.

Summary

Hypersalivation (sialorrhea) is a common complaint of patients with neurodegenerative disorders such as Parkinson’s disease or amyotrophic lateral sclerosis and a frequently disabling side effect of atypical antipsychotic drugs. Conventional treatment including oral anticholinergic or antihistamine medication is often limited by adverse effects and lack of efficacy. Over the past few years, several studies reported decreased drooling after injections of botulinum toxin into the salivary glands. This review describes the current state of treatment of sialorrhea with botulinum toxin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Ahnert-Hilger G, Bigalke H (1995) Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog Neurobiol 46:83–96

    Article  CAS  PubMed  Google Scholar 

  2. Arnold HG, Gross CW (1977) Transtympanic neurectomy: a solution to drooling problems. Dev Med Child Neurol 19:509–513

    CAS  PubMed  Google Scholar 

  3. Bai Y-M, Lin C-C, Chen J-Y et al. (2001) Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol 21:608–611

    Article  CAS  PubMed  Google Scholar 

  4. Bateson MC, Gibberd FB, Wilson RS (1973) Salivary symptoms in Parkinson disease. Arch Neurol 29:274–275

    CAS  PubMed  Google Scholar 

  5. Bagheri H, Damase-Michel C, Lapeyre-Mestre M et al. (1999) A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol 22:213–215

    CAS  PubMed  Google Scholar 

  6. Ben-Areyh H, Jungemann T, Szargel R et al. (1996) Salivatory flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biol Psychiatry 39:946–949

    Article  PubMed  Google Scholar 

  7. Benninghoff, Drenckhahn (2002) Anatomie Bd 1, 16. Aufl. Elsevier, Urban und Fischer, München

  8. Beuche W, Arglebe C, Laskawi R (2000) Quantitative reduction of saliva production in two ALS patients with intraglandular injections of botulinum toxin. Neurol Psychiatr Brain Res 8:23–26

    Google Scholar 

  9. Bhatia KP, Münchau A, Brown P (1999) Botulinum toxin is a useful treatment in excessive drooling of saliva. J Neurol Neurosurg Psychiatry 67:697

    CAS  Google Scholar 

  10. Bigalke H (2001) Botulinumtoxine: Wirksamkeit und Antigenität. Klin Neurophysiol 32(4):210–213

    Article  Google Scholar 

  11. Bigalke H, Shoer L (2000) Clostridal neurotoxins. Handbook Exp Pharm 145:407–444

    CAS  Google Scholar 

  12. Brodtkorb E, Wyzocka-Bakowska MM, Lillevold PE et al. (1988) Transdermal scopolamine in drooling. J Ment Defic Res 32:233–237

    PubMed  Google Scholar 

  13. Bushara KO (1997) Sialorrhea in amytrophic lateral sclerosis: a hypothesis of a new treatment Botulinum toxin A injections of the parotid glands. Med Hypothesis 48:337–339

    CAS  Google Scholar 

  14. Calderon J, Rubin E, Sobota WL (2000) Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report. Int Clin Psychopharmacol 15:49–52

    CAS  PubMed  Google Scholar 

  15. Copp PJ, Lament R, Tennent TG (1991) Amitryptiline in clozapine-induced sialorrhea. Br J Psychiatry 159:166

    CAS  Google Scholar 

  16. Crysdale WS, White A (1989) Submandibular duct relocation for drooling: a 10-year experience with 194 patients. Otolaryngol Head Neck Surg 101:87–92

    CAS  PubMed  Google Scholar 

  17. Dickson C, Shevky R (1923). Studies on the manner in which the toxin of Clostridium botulinum acts upon the body. I. The effect upon the autonomic system. J Exp Med 37:711–731

    Article  Google Scholar 

  18. Duvoisn RC (1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17:124–136

    PubMed  Google Scholar 

  19. Eadie MJ, Tyrer JH (1965) Alimentary disorder in parkisonism. Australas Ann Med 14:13–22

    CAS  PubMed  Google Scholar 

  20. Ekström J, Kemplay SK, Garrett JR et al. (1977) Effect of botulinum toxin on the choline acetyltransferase activity in salivary glands of cats. Experientia 33:1458–1460

    PubMed  Google Scholar 

  21. Ellies M, Laskawi R, Götz W et al. (1999) Immunohistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat. Eur Arch Otorhinolaryngol 256:148–152

    Article  CAS  PubMed  Google Scholar 

  22. Ellies M, Laskawi R, Rohrbach-Volland S et al. (2002) Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope 112:82–86

    Article  CAS  PubMed  Google Scholar 

  23. Ellies M, Laskawi R, Rohrbach-Volland S et al. (2003) Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 61:454–457

    Article  PubMed  Google Scholar 

  24. Enfors B (1962) The parotid and submandibular secretion in man. Quantitative recordings of the normal and pathological activity. Acta Otolaryngol 172(Suppl):1–67

    Google Scholar 

  25. Frueh BR, Felt DP, Wojno TH et al. (1984) Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol 102:1464–1468

    CAS  PubMed  Google Scholar 

  26. Giess R, Naumann M, Werner E et al. (2000) Injections of botulinum toxin A into the salivary glands improve sialorrhea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 69:121–123

    Article  CAS  PubMed  Google Scholar 

  27. Glickman S, Deaney CN (2001) Treatment of relative sialorrhea with botulinum toxin type A: description and rationale for an injection procedure with case report. Eur J Neurol 8:567–571

    Article  CAS  PubMed  Google Scholar 

  28. Grabowski J (1992) Clonidine treatment for clozapine induced hypersalivation. J Clin Psychopharmacol 12:69–70

    CAS  PubMed  Google Scholar 

  29. Hyson HC, Johnson A, Jog MS (2001) Survey of sialorrhea in parkinsonian patients in southwestern Ontario. Can J Neurol Sci 28:S46–S47

    Google Scholar 

  30. Hyson HC, Johnson AM, Mandar SJ (2002) Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 17:1318–1320

    Article  PubMed  Google Scholar 

  31. Johnston BT, Li Q, Castell JA, Castell DO (1995) Swallowing and esophageal function in Parkinson’s disease. Am J Gastroenterol 90:1741–1746

    CAS  PubMed  Google Scholar 

  32. Jost WH (1999) Treatment of drooling in Parkinson’s disease with Botulinum toxin. Mov Disord 14:1057

    Article  CAS  Google Scholar 

  33. Jost WH, Naumann M (2001) Seltenere und neuere Indikationen für Botulinumtoxin. Klin Neurophysiol 32(4):232–236

    Article  Google Scholar 

  34. Kahl KG, Hagenah J, Zapf S et al. (2004) Botulinum toxin as an effective treatment of clozapine-induced hypersalivation. Psychopharmacology 173:229–230

    Article  CAS  PubMed  Google Scholar 

  35. Kerner J (1817) Vergiftung durch verdorbene Würste. Tübinger Blätt Naturwissenschaften Arzneykunde 3:1–25

  36. Kerner J (1822) Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus. Ein Beitrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Cotta, Stuttgart

  37. Koller WC (1984) Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 20:307–311

    CAS  PubMed  Google Scholar 

  38. Lipp A, Trottenberg T, Schink T et al. (2003) A randomised trial of botulinum toxin A for treatment of drooling. Neurology 61:1279–1281

    CAS  PubMed  Google Scholar 

  39. Maisey EA, Wadsworth JD, Poulain B et al. (1988) Involvement of the constituent chains of botulinum neurotoxin A and B in the blockade of neurotransmitter release. Eur J Biochem 177:683–691

    CAS  PubMed  Google Scholar 

  40. Mann AC (1994) Localised autonomic failure due to botulinum toxin A injection. J Neurol Neurosurg Psychiatry 57:1320

    CAS  PubMed  Google Scholar 

  41. Mancini F, Zangaglia R, Cristina S et al. (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin Type A in the treatment of drooling in parkinsonism. Mov Disord 18:685–688

    Article  PubMed  Google Scholar 

  42. Marinkovic D, Timotijevic I, Babinski T et al. (1994) The side effects of Clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 18:537–544

    Article  CAS  PubMed  Google Scholar 

  43. Naumann M, Giess R, Schwager K et al. (2001) Botulinum toxin for the treatment of sialorrhea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 70:417–418

    Article  PubMed  Google Scholar 

  44. Ondo WG, Hunter C, Moore W (2004) A double-blind placebo trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 62:37–40

    CAS  PubMed  Google Scholar 

  45. Pal PK, Calne DB, Calne S et al. (2000) Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54:244–247

    CAS  PubMed  Google Scholar 

  46. Racette BA, Good L, Sagitto S et al. (2003) Botulinum toxin B reduces sialorrhea in Parkinsonism. Mov Disord 18(9):1059–1061

    Article  PubMed  Google Scholar 

  47. Rapp D (1980) Drool control: long-term follow-up. Dev Med Child Neurol 22:448–453

    CAS  PubMed  Google Scholar 

  48. Reddihough D, Johnson H, Staples M et al. (1990) Use of trihexyphenidol hydrochloride to control drooling of children with cerebral palsy. Dev Med Child Neurol 32:985–989

    CAS  PubMed  Google Scholar 

  49. Rose FC (1987) The management of motor neuron disease. Adv Exp Med Biol 209:167–174

    CAS  PubMed  Google Scholar 

  50. Schmauss M, Wolff R, Erfurth A et al. (1989) Tolerability of long term clozapine treatment. Psychopharmacology 99(Suppl):S105–108

    PubMed  Google Scholar 

  51. Scott AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 79:734–770

    CAS  PubMed  Google Scholar 

  52. Shaari CM, Wu BL, Biller HF et al. (1998) Botulinum toxin decreases salivation from canine submandibular glands. Otolaryngol Head Neck Surg 118:452–457

    CAS  PubMed  Google Scholar 

  53. Smith RA, Goode RL (1970) Current concepts: sialorrhoea. N Engl J Med 283:917–918

    CAS  PubMed  Google Scholar 

  54. Stalpers LJA, Moser EC (2002) Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology 58:1038

    PubMed  Google Scholar 

  55. Tan EK, LoYL, Seah A et al. (2001) Recurrent jaw dislocation after Botulinum toxin treatment for sialorrhoea in amyotropic lateral sclerosis. J Neurol Sci 190:95–97

    Article  CAS  PubMed  Google Scholar 

  56. Wilkie TF, Brody GS (1977) The surgical treatment of drooling. A ten-year review. Plast Reconstr Surg 59:791–797

    CAS  PubMed  Google Scholar 

  57. Friedmann A, Potulska A (2001) Botulinum toxin for treatment of parkinsonian sialorrhea. Neurol Neurochir Pol 35 [Suppl 3]:23–27

    Google Scholar 

  58. Porta M, Gamba M, Bertacchi G, Vaj P (2001) Treatment of sialorrhea with ultrasound guided botulinum toxin type A injection in patients with neurological disordes. J Neurol Neurosurg Psychiatry 70:538–540

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Universität Lübeck

    J. Hagenah & C. Klein

  2. Klinik für Psychiatrie und Psychotherapie, Universität Lübeck

    K. G. Kahl, S. Steinlechner & R. Lencer

  3. Klinik für Neurologie, Ratzeburger Allee 160, 23538, Lübeck, Deutschland

    J. Hagenah

Authors
  1. J. Hagenah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. G. Kahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Steinlechner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Lencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Hagenah.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagenah, J., Kahl, K.G., Steinlechner, S. et al. Die Behandlung der Sialorrhö mit Botulinum-Toxin . Nervenarzt 76, 418–425 (2005). https://doi.org/10.1007/s00115-004-1799-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-004-1799-z

Schlüsselwörter

Keywords

Search

Navigation